CD8A and non-small cell lung carcinoma: In a series of 1552 NSCLC patients, Ricciuti et al. demonstrated that higher TMB was significantly associated with improved therapy response, CD8+ T-cell infiltration, and survival after PD-1/PD-L1 inhibitor therapy [147].